अगला

स्वत: प्ले

Osimertinib in Advanced Non–Small-Cell Lung Cancer

2 विचारों • 07/04/23
शेयर करना
एम्बेड
administrator
administrator
ग्राहकों
0

EGFR tyrosine kinase inhibitors are standard treatment for non small-cell lung cancer. Despite high tumor response rates, disease progresses in most patients after 9 to 13 months. Is there a way to lengthen progression-free survival? New research findings are summarized in this short video. Full study: http://nej.md/2gymJkj

और दिखाओ
0 टिप्पणियाँ sort इसके अनुसार क्रमबद्ध करें
फेसबुक टिप्पणियाँ

अगला

स्वत: प्ले